Search results
Growing Together is the theme of combined culture. Mumbai, India: March 25, 2015 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715), today, begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months ...
Annual Report 2002. At Sun, we remain committed to creating long term value for Ranbaxy Archives Annual Report. In line with this philosophy, we will continue to focus on performance and producing consistent returns.
If you have any questions about Ranbaxy OTC products, please contact Ranbaxy OTC Customer Service at 1-877-OHM-LABS. ... DUSA Pharmaceuticals, Inc., 25 Upton Drive ...
May 1, 2014 · In April 2014, Sun Pharmaceutical acquired 100% of Ranbaxy Laboratories for $4 billion to create world’s fifth largest specialty generic pharma company. Under these agreements, Ranbaxy will merge into Sun Pharma and the shareholders of Ranbaxy will receive 0.8 shares of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an ...
Mumbai and Gurgaon, India: December 8, 2014 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and Ranbaxy Laboratories Ltd (Reuters: RANB.BO, Bloomberg: RBXY IN, NSE: RANBAXY, BSE: 500359) today announced that they have received the order of the Competition Commission of India (“CCI ...
Mar 25, 2015 · Integration is the immediate challenge, said Israel Makov, Sun Pharma’s Chairman, announcing the closure of the company’s $4-billion merger with Ranbaxy Laboratories, making the combined ...
Mar 26, 2015 · Sun Pharma agreed to acquire Ranbaxy from Japan’s Daiichi Sankyo Co. Ltd for $3.2 billion in stock in addition to assuming $800 million of debt. Sun Pharma has made nearly 20 acquisitions since ...
